Surrozen Inc., a startup developing regenerative medicines leveraging tissue-specific Wnt modulation, has raised $50 million in series C financing. Proceeds from the round will be used to advance the company’s top two antibodies to the clinic, one for the treatment of severe liver disease and a second for moderate to severe inflammatory bowel disease (IBD).
Nan Fung Life Sciences is “looking to make a significant presence in the field,” said Engrail Therapeutics Inc. CEO Vikram Sudarsan, whose firm bagged a $32 million series A round led by the global investment platform of Hong Kong’s Nan Fung Group, and its support represents “a clear statement in that direction.”
Orca Bio Inc.’s $192 million series D brings the company out of stealth and openly into the business of transforming allogeneic cell therapies. The new funding brings Orca’s total capital raised since 2016 to nearly $300 million.
DUBLIN – Lassen Therapeutics Inc. is following the Enleofen Bio Pte Ltd. playbook by targeting the interleukin-11 receptor (IL-11R) as a novel approach to combating both fibrosis and cancer. It’s a move that paid off handsomely earlier this year for Singapore-based Enleofen, which entered a broad alliance in fibrosis with Boehringer Ingelheim GmbH, which could generate up to $1 billion in milestones for each product emanating from the partnership. San Diego-based Lassen is now laying claim to that space as well and has just emerged from stealth mode, having closed but not previously disclosed a $31 million series A round.
C4 Therapeutics Inc., a company focused on destroying disease-causing proteins via degradation, has closed a $170 million financing intended to help move four cancer candidates into the clinic by the end of 2022.
LONDON - Ona Therapeutics SL has raised €30 million (US$33.9 million) in a series A round, providing the means to advance a new method of treating metastases by blocking the lipid metabolism of cancer cells.
DUBLIN – Etherna Immunotherapies NV raised €34 million (US$38.2 million) in a series B funding round to progress its pipeline of mRNA-based vaccines for cancer and infectious disease.
RSS
